Role of the Natural Immune System in Control of Primary Tumors and Metastasis

  • Ronald B. Herberman
  • Elieser Gorelik
Chapter

Abstract

Intensive studies of antitumor resistance during the past 25 years have revealed that some tumors in experimental animals can evoke high levels of immune responses against tumor-associated antigens. This immunological response was mostly mediated by T lymphocytes and was found to be extremely efficient in the specific destruction of the tumor target cells in vitro and in inhibition of tumor growth and metastatic spread.(1–4)

Keywords

Natural Killer Cell Natural Killer Cell Activity Natural Killer Activity Large Granular Lymphocyte Antimetastatic Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Baldwin, R. W., 1976, Role of immunosurveillance against chemically induced rat tumors, Transplant Rev. 28:62.PubMedGoogle Scholar
  2. 2.
    Fidler, I. J., Gerstein, D. M., and Hart, I. R., 1978, The biology of cancer invasion and metastasis, Adv. Cancer Res. 28:149.PubMedCrossRefGoogle Scholar
  3. 3.
    Klein, G., and Klein, E., 1977, Rejectability of virus induced tumors and non-rejectability of spontaneous tumors-A lesson in contrasts, Transplant. Proc. 9:1095.PubMedGoogle Scholar
  4. 4.
    Kripke, M., 1981, Immunologic mechanisms in UV radiation carcinogenesis, Adv. Cancer Res. 34:69.PubMedCrossRefGoogle Scholar
  5. 5.
    Hewitt, H. B., Blake, E. R., and Walder, A. S., 1976, A critique of the evidence for active host defense against cancer, based on personal studies of 27 murine tumours of spontaneous origin, Br. J. Cancer 33:241.PubMedCrossRefGoogle Scholar
  6. 6.
    Weiss, D., 1977, The questionable immunogenicity of certain neoplasms, Cancer Immunol. Immunother. 2:11.CrossRefGoogle Scholar
  7. 7.
    Herberman, R. B. (ed.), 1980, Natural Cell-Mediated Immunity Against Tumors, Academic Press, New York.Google Scholar
  8. 8.
    Herberman, R. B. (ed.), 1982, NK Cells and Other Natural Effector Cells, Academic Press, New York.Google Scholar
  9. 9.
    Alexander, P., 1976, The functions of the macrophage in malignant disease, Annu. Rev. Med. 27:207.PubMedCrossRefGoogle Scholar
  10. 10.
    Fidler, I. J., 1974, Inhibition of pulmonary metastases of intravenous injection of specifically activated macrophages, Cancer Res. 34:1074.PubMedGoogle Scholar
  11. 11.
    Hibbs, J. B. Jr., 1974, Discrimination between neoplastic and nonneoplastic cells in vitroactivated macrophages, JNCI 53:1487.PubMedGoogle Scholar
  12. 12.
    Fidler, I., and Poste, G., 1982, Macrophage-mediated destruction of malignant tumor cells and new strategies for the therapy of metastatic disease, Springer Semin. Immunopathol. 5:161.PubMedCrossRefGoogle Scholar
  13. 13.
    Herberman, R. B., Nunn, M. E., and Lavrin, D. H., 1975, Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. I. Distribution of reactivity and specificity, Int. J. Cancer 16:216.PubMedCrossRefGoogle Scholar
  14. 14.
    Kiessling, R., Klein, E., and Wigzell, H., 1975, Natural killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells: Specificity and distribution according to genotype, Eur. J. Immunol 5:112.PubMedCrossRefGoogle Scholar
  15. 15.
    Herberman, R. B., and Holden, H. T., 1978, Natural cell-mediated immunity, Adv. Cancer 27:305.CrossRefGoogle Scholar
  16. 16.
    Kärre, K., Klein, G. O., Kiessling, R., Klein, G., and Roder, J. C., 1980, Low natural in vivoresistance to syngeneic leukaemias in natural killer—deficient mice, Nature 284:624.PubMedCrossRefGoogle Scholar
  17. 17.
    Kiessling, R., Petranyi, G., Klein, G., and Wigzell, H., 1975, Genetic variation of in vitrocytolytic activity in in vivorejection potential of nonimmunized semisyngeneic mice against a mouse lymphoma line, Int. J. Cancer 15:933.PubMedCrossRefGoogle Scholar
  18. 18.
    Kiessling, R., Petranyi, G., Klein, G., and Wigzell, H., 1976, Non-T-cell resistance against a mouse Moloney lymphoma, Int. J. Cancer 17:275.PubMedCrossRefGoogle Scholar
  19. 19.
    Kiessling, R., and Wigzell, H., 1979, An analysis of the murine NK cells as to structure, function, and biological relevance, Immunol. Rev. 44:165.PubMedCrossRefGoogle Scholar
  20. 20.
    Petranyi, G., Kiessling, R., Povey, S., Klein, G., Herzenberg, E., and Wigzell, H., 1976, The genetic control of natural killer cell activity and its association with in vivoresistance against a Moloney lymphoma isograft, Immunogenetics 3:15.CrossRefGoogle Scholar
  21. 21.
    Riesenfeld, I., Orn, A., Gidlund, M., Axberg, I., Aim, G. V. and Wigzell, H., 1980, Positive correlation between in vitroNK activity and in vivoresistance toward AKR lymphoma cells, Int. J. Cancer 25:399.PubMedCrossRefGoogle Scholar
  22. 22.
    Talmadge, J. E., Meyers, K. M., Prieur, D. J., and Starkey, J. R., 1980, Role of NK cells in tumor growth and metastasis in beige mice, Nature 284:622.PubMedCrossRefGoogle Scholar
  23. 23.
    Haller, O., Kiessling, R., Orn, A., Kärre, K., Nilsson, K., and Wigzell, H., 1977, Natural cytotoxicity to human leukemia mediated by mouse non-T cells, Int. J. Cancer 20:93.PubMedCrossRefGoogle Scholar
  24. 24.
    Habu, S., Fukui, H., Shimamura, K., Kasai, M., Nagai, Y., Okumura, K., and Tamaoka, N., 1981, In vivoeffects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice, J. Immunol. 127:34.PubMedGoogle Scholar
  25. 25.
    Gorelik, E., and Herberman, R. B., 1981, Radioisotope assay for evaluation of in vivonatural cell-mediated resistance of mice to local transplantation of tumor cells, Int. J. Cancer 27:709.PubMedCrossRefGoogle Scholar
  26. 26.
    Kasai, M., LeClerc, J. C., McVay-Boudreau, L., Shen, F. W., and Cantor, H., 1979, Direct evidence that natural killer cells in nonimmune spleen cell populations prevent tumor growth in vivo, J. Exp. Med. 149:1260.PubMedCrossRefGoogle Scholar
  27. 27.
    Tam, M. R., Emmons, S. L., and Pollack, S. B., 1980, FACS analysis and enrichment of NK effector cells, in: Natural Cell-Mediated Immunity Against TumorsR. B. Herberman, (ed.), Academic Press, New York, pp. 265–276Google Scholar
  28. 28.
    Brown, J., and Parker, E., 1979, Host treatments affecting artificial pulmonary metastases: Interpretation of loss of radioactivity labelled cells from lungs, Br. J. Cancer 40:677.PubMedCrossRefGoogle Scholar
  29. 29.
    Fidler, I., 1970, Metastasis: Quantitative analysis of distribution and fate of tumor emboli labeled with 125l-5-iodo-2′deoxyuridine, JNCI 45: 773.PubMedGoogle Scholar
  30. 30.
    Hofer, K., Prensky, W., and Hughes, W., 1969, Death and metastatic distribution of tumor cells in mice monitored with 125I-iododeoxyuridine, JNCI 45:763.Google Scholar
  31. 31.
    Gorelik, E., Wiltrout, R., Okumura, K., Habu, S., and Herberman, R., 1982, Role of NK cells in the control of metastatic spread and growth of tumor cells in mice, Int. J. Cancer 30:107.PubMedCrossRefGoogle Scholar
  32. 32.
    Hanna, N., and Fidler, I. J., 1980, The role of natural killer cells in the destruction of tumor emboli, JNCI 65:801.PubMedGoogle Scholar
  33. 33.
    Hanna, N., and Fidler, I. J., 1981, Expression of metastatic potential of allogeneic circulating and xenogenic neoplasms in young nude mice, Cancer Res. 41:438.PubMedGoogle Scholar
  34. 34.
    Riccardi, D., Puccetti, P., Santoni, A., and Herberman, R. B., 1979, Rapid in vivoassay of mouse NK cell activity, JNCI 63:1041.PubMedGoogle Scholar
  35. 35.
    Riccardi, C., Barlozzari, T., Santoni, A., Herberman, R., and Cesarini, C., 1981, Transfer to cyclophosphamide-treated mice of natural killer (NK) cells and in vivonatural reactivity against tumors, J. Immunol. 126:1284.PubMedGoogle Scholar
  36. 36.
    Hanna, N., 1980, Expression of metastatic potential of tumor cells in young nude mice correlated with low levels of natural killer cell-mediated cytotoxicity, Int. J. Cancer 26:675.PubMedCrossRefGoogle Scholar
  37. 37.
    Hanna, N., 1982, Role of natural killer cells in control of cancer metastasis, Cancer Metastasis Rev. 1:45.PubMedCrossRefGoogle Scholar
  38. 38.
    Gorelik, E., and Herberman, R. B., 1981, Inhibition of the activity of mouse NK cells by urethane, JNCI 66:543.PubMedGoogle Scholar
  39. 39.
    Seaman, W., Blackman, M., Gindhart, T., Roubinia, J., Loeb, J., and Talal, N., 1978, β-Estradiol reduced natural killer cells in mice, J. Immunol. 12:2193.Google Scholar
  40. 40.
    DeBrabancer, M., Aerts, F., and Borgers, M., 1974, The influence of a glucocorticoid on the lodgement and development in the lungs of intravenously injected tumour cells, Eur. J. Cancer 10:755.Google Scholar
  41. 41.
    Hanna, N., and Schneider, M., 1983, Enhancement of tumor metastasis and suppression of natural killer cell activity by β-estradiol treatment, J. Immunol. 130:974.PubMedGoogle Scholar
  42. 42.
    Steele, G., and Adams, K., 1977, Enhancement by cytotoxic agents of artificial pulmonary metastasis, Br. J. Cancer 36:653,CrossRefGoogle Scholar
  43. 43.
    Pollack, S., 1982, Direct evidence for anti-tumor activity by NK cells in vivo: Growth of B16 melanoma in anti-NK 1.1 treated mice, in: NK Cells and Other Natural Effector Cells (R. B. Herberman, ed.), Academic Press, New York, pp. 1347–1352.Google Scholar
  44. 44.
    Gorelik, E., Bere, E., and Herberman, R., 1984, Role of NK cells in the antimetastatic effect of anticoagulant drugs, Int. J. Cancer 33:87.PubMedCrossRefGoogle Scholar
  45. 45.
    Djeu, J. Y., Heinbaugh, J. A., Holden, H. T., and Herberman, R. B., 1979, Role of macrophages in the augmentation of mouse natural killer cell activity by poly I:C and interferon, J. Immunol. 122:182.PubMedGoogle Scholar
  46. 46.
    Herberman, R. B., Djeu, J. Y., Kay, H. D., Ortaldo, J. R., Riccardi, C., Bonnard, G. D., Holden, H. T., Fagnani, R., Santoni, A., and Puccetti, P., 1979, Natural killer cells: Characteristics and regulation of activity, Immunol. Rev. 44:43.PubMedCrossRefGoogle Scholar
  47. 47.
    Herberman, R. B., Ortaldo, J. R., Djeu, J. Y., Holden, H. T., Jett, J., Lang, N. P., and Pestka, S., 1980, Role of interferon in regulation of cytotoxicity of natural killer cells and macrophages, Ann. N.Y. Acad. Sci. 250:63.CrossRefGoogle Scholar
  48. 48.
    Herberman, R. B., Brunda, M. J., Djeu, J. Y., Domzig, W., Goldfarb, R. H., Holden, H., Ortaldo, J. R., Reynolds, C. W., Riccardi, C., Santoni, A., Stadler, B. M., and Timonen, T., 1982, Immunoregulation and natural killer cells, in: Natural Killer Cells. Volume 4: Human Cancer Immunology (B. Serrou, C. Rosenfeld, and R. B. Herberman, eds.), Elsevier/North-Holland, Amsterdam, pp. 37–52.Google Scholar
  49. 49.
    Hanna, N., and Burton, R., 1981, Definitive evidence that natural killer (NK) cells in experimental tumor metastasis in vivo, J. Immunol. 127:1754.PubMedGoogle Scholar
  50. 50.
    Barlozzari, T., Reynolds, C., and Herberman, R., 1983, In vivorole of natural killer cells: Involvement of large granular lymphocytes in the clearance of tumor cells in anti–asialo GM1–treated rats, J. Immunol. 131:1024.PubMedGoogle Scholar
  51. 51.
    Chow, D., Brown, G., and Greenberg, A., 1982, NK cell and NAB antitumor activity in vivo, in: NK Cells and Other Natural Effector Cells (R. Herberman, ed.), Academic Press, New York, pp. 1379–1386.Google Scholar
  52. 52.
    Gale, R. P., and Zighelboim, J., 1975, Polymorphonuclear leukocytes in antibody-dependent cellular cytotoxicity, J. Immuol 114:1047.Google Scholar
  53. 53.
    Korec, S., 1980, The role of granulocytes in host defense against tumors, in: Natural Cell-Mediated Immunity Against Tumors (R. B. Herberman, ed.), Academic Press, New York, pp. 1301–1307.Google Scholar
  54. 54.
    Liotta, L., and DeLisi, C., 1977, Method for quantitating tumor cell removal and tumor cell invasive capacity in experimental metastases, Cancer Res. 37:4003.PubMedGoogle Scholar
  55. 55.
    Bomford, R., and Olivotto, M., 1974, The mechanism of inhibition by Corynebacterium parvumof the growth of lung nodules from intravenously injected tumor cells, Int. J. Cancer 14:226.PubMedCrossRefGoogle Scholar
  56. 56.
    Breard, J., Reinherz, E. L., O’Brien, C., and Schlossman, S. F., 1981, Delineation of an effector population responsible for natural killing and antibody-dependent cellular cytotoxicity in man, Clin. Immunol. Immunopathol. 18:145.PubMedCrossRefGoogle Scholar
  57. 57.
    Brodt, P., Feldman, M., and Segal, S., 1983, Differences in the metastatic potential of two sublines of tumor 3LL selected for resistance to natural NK-like effector cells, Cancer Immunol. Immunother. 16:109.PubMedCrossRefGoogle Scholar
  58. 58.
    Brooks, C., Flannery, G., Willmott, N., Austin, E., Kenwrick, S., and Baldwin, R., 1981, Tumour cells in metastatic deposits with altered sensitivity to natural killer cells, Int. J. Cancer 28:191.PubMedCrossRefGoogle Scholar
  59. 59.
    Gorelik, E., Bere, E., and Herberman, R., 1987, The mechanism for the antimetastatic effect of the anticoagulant drugs: Dependence on NK cell activity, in: Hemostasis and Cancer (L. Muszbek, eds.), CRC Press, Boca Raton, FL, pp. 37–46.Google Scholar
  60. 60.
    Lanza, E., and Djeu, J., 1982, Age-independent natural killer cell activity in murine peripheral blood, in: NK Cells and Other Natural Effector Cells (R. B. Herberman, ed.), Academic Press, New York, pp. 335–340.Google Scholar
  61. 61.
    Puccetti, P., Santoni, A., Riccardi, C., and Herberman, R., 1980, Cytotoxic effector cells with the characteristics of natural killer cells in the lungs of mice, Int. J. Cancer 25:153.PubMedCrossRefGoogle Scholar
  62. 62.
    Stein-Streilein, J., Bennett, M., Mann, D., and Kumar, V., 1983, Natural killer cells in mouse lungs: Surface phenotype, target preference, and response to local influenza virus infection, J. Immunol. 131:2699.PubMedGoogle Scholar
  63. 63.
    Tagliabue, A., Befus, A., Clark, D., and Bienestock, J., 1981, Characteristics of natural killer cells in the murine intestinal epithelium and lamina proipria, J. Exp. Med. 155:1785.CrossRefGoogle Scholar
  64. 64.
    Wiltrout, R., Mathieson, B., Talmadge, J., Reynolds, C., Zhang, S., Herberman, R. B., and Ortaldo, J., 1984, Augmentation of organ-associated NK activity by biological response modifiers: Isolation and characterization of large granular lymphocytes from the liver, J. Exp. Med. 160:1431.PubMedCrossRefGoogle Scholar
  65. 65.
    Wiltrout, R., Herberman, R., Zhang, S., Chirigos, M., Ortaldo, J., Green, K., and Talmadge, J., 1985, Role of organ-associated NK cells in decreased formation of experimental metastasis in lung and liver, J. Immunol. 134:4267.PubMedGoogle Scholar
  66. 66.
    Sadler, T., and Castro, J., 1976, The effects of Corynebacterium parvumand surgery on the Lewis lung carcinoma and its metastases, Br. J. Surg. 63:292.PubMedCrossRefGoogle Scholar
  67. 67.
    Gorelik, E., Fogel, M., Feldman, M., and Segal, S., 1979, Differences in resistance of metastatic tumor cells and cells from local tumor growth to cytotoxicity of natural killer cells, JNCI 63:1397.PubMedGoogle Scholar
  68. 68.
    Gorelik, E., Feldman, M., and Segal, S., 1982, Selection of 3LL tumor subline resistant to natural effector cells concomitantly selected for increased metastatic potency, Cancer Immunol. Immunother. 12:105.Google Scholar
  69. 69.
    Teale, D., Rees, R., Clark, A., Walker, J., and Potter, C., 1983, Reduced susceptibility to natural killer cell lysis of hamster tumours exhibiting high levels of spontaneous metastasis, Cancer Lett. 19:221.PubMedCrossRefGoogle Scholar
  70. 70.
    Hanna, N., and Fidler, I. J., 1981, Relationship between metastatic potential and resistant natural killer cell-mediated cytotoxicity in three murine tumor system, JNCI 66:1183.Google Scholar
  71. 71.
    Segal, S., Kingsmore, S., Gorelik, E., and Feldman, M., 1982, Control by NK cells of the generation of lung metastases by the Lewis lung carcinoma, in: Current Concepts in Human Immunology and Cancer Immunomodulation (B. Serrou et al., eds.), Elsevier/North-Holland, Amsterdam, pp. 227–234.Google Scholar
  72. 72.
    Poupon, M., Judde, J., Pot-Deprun, J., Sweeney, F., and Lespinats, G., 1983, Variable susceptibility to NK activity of cloned cell lines derived from a primary rat rhabdomyosarcoma: Relationship to metastatic potential, Br. J. Cancer 48:75.PubMedCrossRefGoogle Scholar
  73. 73.
    Gerson, J. M., Varesio, L., and Herberman, R. B., 1981, Systemic and in situnatural killer and suppressor cell activities in mice bearing progressively growing murine sarcoma virus-induced tumors, Int. J. Cancer 27:243.PubMedCrossRefGoogle Scholar
  74. 74.
    Gorelik, E., 1983, Resistance of tumor-bearing mice to a second tumor challenge, Cancer Res. 43:138.PubMedGoogle Scholar
  75. 75.
    Gorelik, E., 1985, H-2 antigen expression, immunogenicity and metastatic properties of BL6 melanoma cells treated with MNNG, in: Treatment of Metastasis: Problems and Prospects (K. Hellman, ed.), Taylor and Francis, London, pp. 355–359.Google Scholar
  76. 76.
    Jones, D., Wallace, A., and Fraser, E., 1971, Sequence of events in experimental metastases of Walker-256 tumor: Light, immunofluorescent and electron microscopic observations, JNCI 46:493.PubMedGoogle Scholar
  77. 77.
    Sindelar, W., Tralka, T., and Ketcham, A., 1975, Electron microscopic observation on formation of pulmonary metastases, J. Surg. res. 18:137.PubMedCrossRefGoogle Scholar
  78. 78.
    Wood, J., 1958, Pathogenesis of metastasis formation observed in vivo in the rabbit ear chamber, Arch. Pathol. 66:550.Google Scholar
  79. 79.
    Gasic, G., 1984, Role of plasma, platelets, and endothelial cells in tumor metastasis cancer, Cancer Metastasis Rev. 3:99.PubMedCrossRefGoogle Scholar
  80. 80.
    Karpatkin, S., and Pearlstein, E., 1981, Role of platelets in tumor-cell metastases, Ann. Intern. Med. 95:636.PubMedGoogle Scholar
  81. 81.
    Rickles, R., and Edwards, R., 1983, Activation of blood coagulation in cancer: Trousseau’s syndrome revisited, Blood 62:14.PubMedGoogle Scholar
  82. 82.
    Donati, M., and Poggi, A., 1980, Malignancy and haemostasis, Br. J. Haematol. 44:173.PubMedCrossRefGoogle Scholar
  83. 83.
    Gasic, G., Gasic, T., Galanti, N., Johnson, T., and Murphy, S., 1973, Platelet-tumour-cell interactions in mice: The role of platelets in the spread of malignant disease, Int. J. Cancer 11:704.PubMedCrossRefGoogle Scholar
  84. 84.
    Hilgard, P., 1982, Blood platelets and tumor dissemination, Prog. Clin. Biol. 89:143.Google Scholar
  85. 85.
    Honn, K., Cicone, B., and Skoff, A., 1981, Prostacyclin: A potent antimetastatic agent, Science 212:1270.PubMedCrossRefGoogle Scholar
  86. 86.
    Gorelik, E., 1987, Augmentation of the antimetastatic effects of anticoagulants by immunostimulations in mice, Cancer Res. 47: 809.PubMedGoogle Scholar
  87. 87.
    Gunji, Y., Lewis, J., Herberman, R. B., and Gorelik, E., 1987, Mechanisms of the antimetastatic action of anticoagulants. II. Fibrin coagulation protects tumor cells from destruction by NK or LAK cells. Proc. Am. Assoc. Cancer Res. 28:72.Google Scholar
  88. 88.
    Kärre, K., Ljunggren, M., Piontek, G., Kiessling, R., Klein, G., Taniguchi, K., and Grönberg, A., 1984, Activation of cell-mediated immunity by absence or deleted expression of normal cellular gene products, i.e, by “no self” rather than “non self,” Immunobiology 163:43.Google Scholar
  89. 89.
    Herberman, R. B. (ed.), 1982, NK Cells and Other Natural Effector Cells, Academic Press, New York.Google Scholar
  90. 90.
    Snell, G., and Stevens, L., 1961, Histocompatibility genes of mice. III. H–l and H–4, two histocompatibility loci in the first linkage group, Immunology 4:366.PubMedGoogle Scholar
  91. 91.
    Cudkowicz, G., and Bennett, M., 1971, Peculiar immunobiology of bone marrow allografts. II. Rejection of parental grafts by resistant F1 hybrid mice, J. Exp. Med. 134:1513.PubMedCrossRefGoogle Scholar
  92. 92.
    Carlson, G., and Wegmann, T., 1977, Rapid in vivo destruction of semisyngeneic and allogeneic cells by nonimmunized mice as a consequence of nonidentity at H–2, J. Immunol. 118:2130.PubMedGoogle Scholar
  93. 93.
    Carlson, G., Taylor, B., Marshall, S., and Greenberg, A., 1984, A genetic analysis of natural resistance to nonsyngeneic cells: The role of H–2, Immunogenetics 20:287.PubMedCrossRefGoogle Scholar
  94. 94.
    Klein, G. O., Klein, G., Kiessling, R., and Kärre, K., 1978, H–2 associated control of natural cytotoxicity and hybrid resistance against RBL–5, Immunogenetics 6:561.CrossRefGoogle Scholar
  95. 95.
    Kärre, K., Klein, G. O., Kiessling, R., Argov, S., and Klein, G., 1982, The beige model in studies of natural resistance against semisyngeneic, syngeneic and autochtonous tumors in NK cells and other natural effector cells, in: NK Cells and Other Natural Effector Cells( R. Herberman, eds.), Academic Press, New York, p. 1369.Google Scholar
  96. 96.
    Hansson, M., Kärre, K., Kiessling, R., Roder, J., Andersson, B., and Hayry, P., 1979, Natural NK cell targets in the mouse thymus: Characteristics of the sensitivity cell population, J. Immunol. 123:765.PubMedGoogle Scholar
  97. 97.
    Stern, P., Gidlund, M., Orn, A., and Wigzell, H., 1980, Natural killer cells mediate lysis of embryonal carcinoma cells lacking MHC, Nature 285:341.PubMedCrossRefGoogle Scholar
  98. 98.
    Ljunggren, H., and Kärre, K., 1985, Host resistance directed selectively against H-2 loss lymphoma variants. Analysis of the mechanisms, J. Exp. Med. 162:1745.PubMedCrossRefGoogle Scholar
  99. 99.
    Becker, S., Kiessling, R., Lee, N., and Klein, G., 1978, Modulation of sensitivity to natural killer cell lysis: In vitroexplanation of a mouse lymphoma, JNCI 1:1495.Google Scholar
  100. 100.
    Piontek, G., Taniguchi, K., Ljunggren, H., Gronberg, A., Kiessling, R., Klein, G., and Karre, K., 1985, YAC–1 MHC class I variants reveal an association between decreased NK sensitivity and increased H–2 expression following interferon treatment or in vivopassage, J. Immunol. 135:4281.PubMedGoogle Scholar
  101. 101.
    Taniguchi, K., Kärre, K., and Klein, G., 1985, Lung colonization and metastasis by disseminated B16 melanoma cells: H–2 associated control at the level of the host and the tumor cell, Int. J. Cancer 36:503.PubMedCrossRefGoogle Scholar
  102. 102.
    Harel Bellan, A., Quillet, A., Marchiol, C., DeMars, R., Tursz, T., and Fradelizi, D., 1986, Natural killer susceptibility of human cells may be regulated by genes in the HLA region on chromosome 6, Proc. Natl. Acad. Sci. USA 83:5688.PubMedCrossRefGoogle Scholar
  103. 103.
    DeBaetselier, P., Katzav, S., Gorelik, E., Feldman, M., and Segal, S., 1980, Differential expression of H–2 gene products in tumour cells is associated with their metastogenic properties, Nature 288:179.CrossRefGoogle Scholar
  104. 104.
    Katzav, S., Segal, S., and Feldman, M., 1985, Metastatic capacity of cloned T–10 sarcoma cells that differ in H–2 expression: Inverse relationship to their immunogenic potency, NJCI 74:307.Google Scholar
  105. 105.
    Sowada, Y., Fohring, B., Shenk, T., and Raska, K., 1985, Tumorigenicity of adenovirus-transformed cells: Region El A of adenovirus 12 confers resistance to natural killer cells, Virology 147:413.CrossRefGoogle Scholar
  106. 106.
    Cook, J., Walker, T., Lewis, A., Fuley, H., Graham, R., and Pidler, S., 1986, Expression of the adenovirus El A oncogene during cell transformation is sufficient to induce susceptibility to lysis by host inflammatory cells, Proc. Natl. Acad. Sci. USA 83:6965.PubMedCrossRefGoogle Scholar
  107. 107.
    Gorelik, E., Peppoloni, S., Overton, R., and Herberman, R., 1985, Increase in H–2 antigen expression and immunogenicity of BL6 melanoma cells treated with N-methyl- N-nitro-nitrosoguanidine, Cancer Res. 45: 5341.PubMedGoogle Scholar
  108. 108.
    Chratchko, Y., Van Obbengham, E., Kiger, N., and Feldman, M., 1983, Immunoprecipitation of insulin receptor by antibodies against class I antigens of the murine H–2 major histocompatibility complex, FEBS Lett. 163:207.CrossRefGoogle Scholar
  109. 109.
    Schreiber, A., Schlesenger, A., and Edidin, M., 1984, Interaction between major histocompatibility complex antigen and epidermal growth factor receptor on human cells, J. Mol. Biol. 98:725.Google Scholar
  110. 110.
    Dent, P. B., Fish, L. A., White, J. F., and Good, R. A., 1966, Chediak-Higashi syndrome. Observations on the nature of the associated malignancy, Lab Invest. 15:1634.PubMedGoogle Scholar
  111. 111.
    Roder, J. C., Haliotis, T., Klein, M., Korec, S., Jett, J. R., Ortaldo, J., Herberman, R. B., Katz, P., and Fauci, A. S., 1980, A new immunodeficiency disorder in humans involving NK cells, Nature 284:553.PubMedCrossRefGoogle Scholar
  112. 112.
    Roder, J. C., Laing, L., Haliotis, T., and Kozbor, D., 1982, Genetic control of human NK function, in: Natural Killer Cells. Human Cancer Immunology, Volume 4 (B. Serrou, C. Rosenfeld, and R. B. Herberman, eds.) Elsevier/North-Holland, Amsterdam, pp. 169–186.Google Scholar
  113. 113.
    Roder, J., and Duwe, A., 1979, The beige mutation in the mouse selectively impairs natural killer cell function, Nature 278:451.PubMedCrossRefGoogle Scholar
  114. 114.
    Roder, J. C., Lohmann-Matthes, M.-L., Domzig, W., and Wigzell, H., 1979, The beige mutation in the mouse. II. Selectivity of the natural killer (NK) cell defect, J. Immunol 123:2174.PubMedGoogle Scholar
  115. 115.
    Brunda, M. J., Holden, H. T., and Herberman, R. B., 1980, Augmentation of natural killer cell activity of beige mice by interferon and interferon inducers, in: Natural Cell-Mediated Immunity Against Tumors( R. B. Herberman, ed.), Academic Press, New York.Google Scholar
  116. 116.
    Loutit, J. F., Townsend, K. M. S., and Knowles, J. F., 1980, Tumour surveillance in beige mice, Nature 285:66.CrossRefGoogle Scholar
  117. 117.
    Haliotis, T., Roder, J., and Dexter, D., 1982, Evidence for in vivo NK reactivity against primary tumors, in: NK Cells and Other Natural Effector Cells(R. B. Herberman, ed.), Academic Press, New York, pp. 1399–1404Google Scholar
  118. 118.
    Purtilo, D. T., DeFlorio, D., Hutt, M. Bhawan, J., Yang, J. P. S., Otto, R., and Edward, W., 1977, Variable phenotypic expression of an X-linked recessive lymphoproliferative syndrome, N. Engl. J. Med. 297:1077PubMedCrossRefGoogle Scholar
  119. 119.
    Sullivan, J. L., Byron, K. S., Brewster, F. E., and Purtilo, D. T., 1980. Deficient natural killer cell activity in X-linked lymphoproliferative syndrome, Science 210:543.PubMedCrossRefGoogle Scholar
  120. 120.
    Seeley, J. K., Bechtold, T., Purtilo, D. T., and Lindsten, T., 1982, Deficiency in X-linked lymphoproliferative syndrome, In: NK Cells and Other Natural Effector Cells(R. B. Herberman, ed.), Academic Press, New York, pp. 1211–1218Google Scholar
  121. 121.
    Masucci, M. G., Bejarano, M. T., Vanky, F., and Klein, E., 1982, Cytotoxic and cytostatic activity of human large granular lymphocytes against allogeneic tumor biopsy cells and autologous EBV infected B lymphocytes, in: NK Cells and Other Natural Effector Cells(R. B. Herberman, ed.), Academic Press, New York, pp. 1047–1054Google Scholar
  122. 122.
    Penn, I., and Starzl, T. E., 1972, A summary of the status of do novocancer in transplant recipients, Transplant. Proc. 47:719.Google Scholar
  123. 123.
    Lipinski, M., Tursz, T., Kreis, H., Finale, Y., and Amiel, J. L., 1980, Dissociation of natural killer cell activity and antibody-dependent cell-mediated cytotoxicity in kidney allograft recipients receiving high-dose immunosuppressive therapy, Transplantation 29:214.PubMedCrossRefGoogle Scholar
  124. 124.
    Yoda, Y., Abe, T., Mitamura, K., Saito, K., Kawada, K., Onozawa, Y., Adachi, Y., and Nomura, T., 1982, Deficient natural killer (NK) cell activity in paroxysmal nocturnal haemoglobinuria (PNH), Br. J. Haematol. 52:559.PubMedCrossRefGoogle Scholar
  125. 125.
    Hersey, P., Edwards, A., Honeyman, M., and McCarthy, W. H., 1979, Low natural killer cell activity in familial melanoma patients and their relatives, Br. J. Cancer 40:113.PubMedCrossRefGoogle Scholar
  126. 126.
    Strayer, D. R., Carter, W. A., Mayberry, S. D., Pequignot, E., and Brodsky, I., 1984, Low natural cytotoxicity of peripheral blood mononuclear cells in individuals with high familial incidences of cancer, Cancer Res. 44: 370.PubMedGoogle Scholar
  127. 127.
    Stutman, O ., 1975, Immunodepression and malignancy, in: Advances in Cancer Research, Volume 22 (G. Klein, S. Weinhouse, and B. Haddam, eds.), Academic Press, New York, pp. 261–422Google Scholar
  128. 128.
    Gorelik, E., and Herberman, R. B., 1981, Inhibition of the activity of mouse NK cells by urethane, JNCI 66:543.PubMedGoogle Scholar
  129. 129.
    Gorelik, E., and Herberman, R. B., 1981, Susceptibility of various strains of mice to urethane-induced lung tumors and depressed natural killer cell activity, JNCI 67:1317.PubMedGoogle Scholar
  130. 130.
    Gorelik, E., and Herberman, R. B., 1981, Role of natural-cell-mediated immunity in urethane-induced lung carcinogenesis, in: NK Cells and, Other Natural Effector Cells(R. B. Herberman, ed.), Academic Press, New York, pp. 1415–1421Google Scholar
  131. 131.
    Ehrlich, R., Efrati, M., and Witz, I. P., 1980, Cytotoxicity and cytostasis medicated by splenocytes of mice subjected to chemical carcinogens and of mice bearing primary tumors, in: Natural Cell-Mediated Immunity Against Tumors(R. B. Herberman, ed.), Academic Press, New York, pp. 997–1010Google Scholar
  132. 132.
    Hochman, P. S., Cudkowicz, G., and Dausset, J., 1978, Decline of natural killer cell activity in sublethally irradiated mice, JNCI 61:265.PubMedGoogle Scholar
  133. 133.
    Gorelik, E., and Herberman, R. B., 1982, Depression of natural antitumor resistance of C57BL/6 mice by leukemogenic doses of radiation and restoration of resistance by transfer of bone marrow of spleen cells from normal, but not beige, syngeneic mice, JNCI 69:89.PubMedGoogle Scholar
  134. 134.
    Parkinson, D. R., Brightman, R. P., and Waksal, S. D., 1981, Altered natural killer cell biology in C57BL/6 mice after leukemogenic split-dose irradiation, J. Immunol. 126:1460.PubMedGoogle Scholar
  135. 135.
    Datta, S. K., Priest, E. L., and Trentin, J. J., 1982, Possible role of NK cells in radiation leukemogenesis: Adoptive repair of NK deficit of fractionally irradiated mice by marrow transfusion, in: NK Cells and Other Natural Effector Cells(R. B. Herberman, ed.), Academic Press, New York, pp. 1411–1414Google Scholar
  136. 136.
    Kaplan, H. S., Brown, M. B., and Paull, J., 1966, Influence of bone marrow injections on involution and neoplasia of mouse thymus after systemic irradiation, JNCI 4:303.Google Scholar
  137. 136a.
    Warner, J. F., and Dennert, G., 1982, In vivo function of a cloned cell line with NK activity: Effects on bone marrow transplants, tumor development and metastasis, Nature 300:3.CrossRefGoogle Scholar
  138. 137.
    Trentin, J. J., Datta, S. K., Priest, E. L., Gallagher, M. T., and Nasrallah, A. G., 1982, Transfer of NK activity and lymphoma resistance to AKR mice by marrow from high NK, lymphoma-resistant C57xAKR F1 mice, in: NK Cells and Other Natural Effector Cells(R. B. Herberman, ed.), Academic Press, New York, pp. 1405–1409Google Scholar
  139. 138.
    Kalland, T ., 1982, Effect of depression of NK activity by neonatal exposure to diethylstilbestrol in susceptibility to transplanted and primary carcinogen-induced tumors, in: NK Cells and Other Natural Effector Cells(R. B. Herberman, ed.), Academic Press, New York, pp. 1437–1444Google Scholar
  140. 139.
    Stutman, O ., 1983, The immunological surveillance hypothesis, in: Basic and Clinical Tumor Immunology(R. B. Herberman, ed.), Nijhoff, Boston, pp. 155–194Google Scholar
  141. 140.
    Heston, W., and Dunn, T., 1951, Tumor development is susceptible strain A and resistant lung transplants in LAF1 host, JNCI 11:1057.PubMedGoogle Scholar
  142. 141.
    Maluish, A., Ortaldo, J., Conlon, J., Sherwin, S., Leavitt, R., Strong, D., Weirnik, P., Oldham, R., and Herberman, R. B., 1983, Depression of natural killer cytotoxicity after in vivoadministration of recombinant leukocyte interferon, J. Immunol. 131:503.PubMedGoogle Scholar
  143. 142.
    Santoni, A., Riccardi, C., Barlozzari, T., and Herberman, R., 1980, Suppression of activity of mouse natural killer (NK) cells by activated macrophages from mice treated with pyran copolymer, Int. J. Cancer 26:837.PubMedCrossRefGoogle Scholar
  144. 143.
    Savary, C., and Lotzova, E., 1978, Suppression of natural killer cell cytotoxicity by splenocytes from Corynebacterium paruum—injected bone marrow tolerant and infant mice, J. Immunol. 120:239.PubMedGoogle Scholar
  145. 144.
    Gorelik, E., Wiltrout, R., Brunda, M., Holden, H., and Herberman, R., 1982, Augmentation of metastasis formation by thioglycollate-elicited macrophages, Int. J. Cancer 29:575.PubMedCrossRefGoogle Scholar
  146. 145.
    Gorelik, E., Wiltrout, R., Copeland, D., and Herberman, R., 1985, Modulation of formation of tumor metastases by peritoneal macrophages elicited by various agents, Cancer Immunol. Immunother. 19:35.PubMedCrossRefGoogle Scholar
  147. 146.
    Gorelik, E., Wiltrout, R., Brunda, M., Bere, W., and Herberman, R., 1985, Influence of adoptively transferred thioglycollate-elicited peritoneal macrophages on metastasis formation in mice with depressed or stimulated NK activity, Clin. Exp. Metastasis 3:111.PubMedCrossRefGoogle Scholar
  148. 147.
    Zacharski, L ., 1981, Anticoagulation in the treatment of cancer in man, in: Malignancy and the Hemostatic System(M. Donati, J., Davidson, and S. Garattini, eds.), Raven Press, New York, pp. 113–127Google Scholar
  149. 148.
    Landazuri, M. O., Silva, A., Alvarez, J., and Herberman, R. B., 1979, Evidence that natural cytotoxicity and antibody dependent cellular cytotoxicity are mediated in hu¬mans by the same effector cell populations, J. Immunol. 123:252.PubMedGoogle Scholar
  150. 149.
    Rosenberg, S. A., Lotze, M. T., Muul, L. M., Leitman, S., Chang, A. E., Ettinghausen, S. E., Matory, Y. L., Skibber, J. M., Shiloni, E., Vetto, J. J., Seipp, C. A., Simpson, C., and Reichert, C. M., 1985, Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer, N. Engl. J. Med. 313:1485.PubMedCrossRefGoogle Scholar
  151. 150.
    Clark, M., Hager, M., Gosnell, M., Stadtman, N., and Shapiro, D., 1985, Search for a cure, Newsweek Dec. 16, p. 60Google Scholar
  152. 151.
    Bylinsky, G ., 1985, Science scores a cancer breakthrough, Fortune Nov. 25, p. 16.Google Scholar
  153. 152.
    Grimm, E. A., Mazumder, A., Zhang, H. Z., and Rosenberg, S. A., 1982, Lymphokine activated killer cell phenomenon, lysis of natural killer resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes, J. Exp. Med. 155:823.CrossRefGoogle Scholar
  154. 153.
    Rosenstein, M., Yron, I., Kaufmann, T., and Rosenberg, S. A., 1984, Lymphokine activated killer cells: Lysis of fresh syngeneic NK-resistant murine tumor cells by lym¬phocytes cultured in interleukin 2, Cancer Res, 44: 1946.PubMedGoogle Scholar
  155. 154.
    Herberman, R. B., Balch, C., Bolhuis, R., Golub, S., Hiserodt, J. C., Lanier, L., Lotzova, E., Phillips, J., Riccardi, C., Ritz, J., Santoni, A., Schmidt, R., Uchida, A., and Vujanovic, N., 1987, Lymphokine-activated killer cell activity: Characteristics of effector cells and their progenitors in blood and spleen, Immunol. today 8:178.CrossRefGoogle Scholar
  156. 155.
    Rosenberg, S. A., and Terry, W., 1977, Passive immunotherapy of cancer in animals and man, Adv. Cancer Res. 25:323.PubMedCrossRefGoogle Scholar
  157. 156.
    Herberman, R. B., 1982, Natural killer cells, Hosp. Pract. 17:99.Google Scholar
  158. 157.
    Kedar, E., and Weiss, D. W., 1983, the in vitro generation of effector lymphocytes and their employment in tumor immunotherapy, Adv. Cancer Res. 38:171.PubMedCrossRefGoogle Scholar
  159. 158.
    Kedar, E., Ikejiri, B. L., Gorelik, E., and Herberman, R. B., 1982, Natural cell-mediated cytotoxicity in vitroand inhibition of tumor growth in vivo by murine lymphoid cells cultured with T cell growth factor (TCGF), Clin. Immunol. Immunother. 13:14.Google Scholar
  160. 159.
    Mule, J. J., Shu, S., and Rosenberg, S. A., 1985, The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo, J. Immunol. 135:646.PubMedGoogle Scholar
  161. 160.
    Ettinghausen, S. E., Lipford, E. N., Mule, J. J., and Rosenberg, S. A., 1985, Recombinant interleukin 2 stimulates in vivoproliferation of adaptively transferred lymphokine-activated (LAK) cells, J. Immunol. 135:3623.PubMedGoogle Scholar
  162. 161.
    Salup, R. R., and Wiltrout, R. H., 1986, Adjuvant immunotherapy of established murine renal cancer by interleukin 2-stimulated cytotoxic lymphocytes, Cancer Res. 46: 3358.PubMedGoogle Scholar
  163. 162.
    Salup, R. R., and Wiltrout, R. H., 1986, Treatment of adenocarcinoma in the peritoneum of mice: Chemoimmunotherapy with IL-2-stimulated cytotoxic lymphocytes as a model for treatment of minimal residual disease, Cancer Immunol. Immunother. 22:31.PubMedCrossRefGoogle Scholar
  164. 163.
    Shu, S., Chou, T., and Rosenberg, S. A., 1987, Generation from tumor-bearing mice with in vivo therapeutic efficacy, J. Immunol. 139:295.PubMedGoogle Scholar
  165. 164.
    Chang, A. E., Shu, S., Chou, T., Lafreniere, R., and Rosenberg, S. A., 1986, Differences in the effects of host suppression on the adoptive immunotherapy of subcutaneous and visceral tumors, Cancer Res. 46: 3426.PubMedGoogle Scholar
  166. 165.
    Cheever, M. A., Greenberg, P. D., and Fefer, A., 1981, Specific adoptive therapy of established leukemia with syngeneic lymphocytes sequentially immunized in vivoand in vitroand nonspecifically expanded by culture with interleukin 2, J. Immunol. 126:1318.PubMedGoogle Scholar
  167. 166.
    Cheever, M. A., Greenberg, P. D., Fefer, A., and Gillis, S., 1982, Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivoadministration of purified interleukin 2, J. Exp. Med. 155:968.PubMedCrossRefGoogle Scholar
  168. 167.
    Eberlein, T. J., Rosenstein, M., and Rosenberg, A., 1982, Regression of a disseminated solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2, J. Exp. Med. 156:385.PubMedCrossRefGoogle Scholar
  169. 168.
    Eberlein, T. J., Rosenstein, M., Spiess, P., Wesley, R., and Rosenberg, S. A., 1982, Adoptive chemoimmunotherapy of a syngeneic murine lymphoma with long-term lymphoid cell lines expanded in T cell growth factor, Cancer Immunol. Immunother. 13:5.PubMedCrossRefGoogle Scholar
  170. 169.
    Mule, J. J., Rosenstein, M., Shu, S., and Rosenberg, S. A., 1985, Eradication of a disseminated syngeneic mouse lymphoma by systemic adoptive transfer of immune lymphocytes and its dependence upon a host component(s), Cancer Res. 45: 526.PubMedGoogle Scholar
  171. 170.
    Vujanovic, N. L., Herberman R. B., Al Maghazarchi, A., and Hiserodt, J. C., 1988, Lymphokine-activated killer cells in rats: III. A simple method for the purification of large granular lymphocytes and their rapid expansion and conversion into lymphokine activated killer cells, J. Exp. Med. 167:15.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1989

Authors and Affiliations

  • Ronald B. Herberman
    • 1
  • Elieser Gorelik
    • 2
  1. 1.Departments of Medicine and PathologyPittsburgh Cancer InstitutePittsburghUSA
  2. 2.Departments of PathologyUniversity of Pittsburgh School of MedicinePittsburghUSA

Personalised recommendations